Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

S2S hosts students from Newark Science Park High School for a day of hands-on science

Students 2 Science, Inc. hosted students from Newark Science Park High School for a day of hands-on science as part of its year-long "Supercharged Science" program.

7 May 2010

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

NewCardio, Inc., a cardiac diagnostic technology provider, will unveil its patented CardioBip technology for remote wireless 12-lead detection and monitoring of atrial fibrillation, ischemia and other cardiovascular events at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.

7 May 2010

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

Nile Therapeutics, Inc., a company focused on the development of novel therapeutics for heart failure patients, today announced that it has completed the dose escalation stage of an ongoing Phase II study of CD-NP in patients with acute decompensated heart failure. Nile had previously announced that the study, NIL-CDNP-CT005, was expanded to permit additional dose exploration prior to proceeding to larger Phase II studies.

7 May 2010

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) are publishing research this week that reveals new insights into how a particular set of human adult stem cells helps repair damaged hearts following a heart attack in laboratory mice.

7 May 2010

NHLBI grants MU $8.47 million for research on cardiovascular diseases

One of the largest medical research grants ever awarded to the University of Missouri was announced today by MU scientists and administrators. The National Institutes of Health grant will help answer important questions about such prevalent health problems as high blood pressure, diabetes and stroke. The conditions are closely associated with cardiovascular disease, which is the leading cause of death in Missouri and the nation.

7 May 2010

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Amira Pharmaceuticals, Inc. announced today that preclinical data from its LPA1 receptor antagonist program has been published in the British Journal of Pharmacology.

7 May 2010

Swedish researchers present a new principle for inhibiting atherosclerosis

7 May 2010

Genzyme to initiate $2 billion stock buyback

Genzyme Corp. today announced that its Board of Directors has voted to pursue several actions to increase shareholder value. The company will initiate a $2 billion stock buyback, under which $1 billion of stock will be repurchased in the near term and financed with debt. The additional $1 billion of stock will be repurchased during the next 12 months.

7 May 2010

Australia’s first ever health policy for men

Prime Minister Kevin Rudd yesterday announced Australia’s first ever men’s health policy called the “National Male Health Policy”. He said in the announcement during a visit to the Whittlesea Men's Shed in Victoria, “They either think that they're invincible that they can just tough it out…'They don't like talking about it usually, and frankly, the problem with all that is it makes it really hard to deal with men's health problems before they become too serious.” He felt this move was long due. He added, “'It's a pretty important time that we do that, we're probably about 110 years late.”

6 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

Measurement of finger temperature to assess individual's risk for CVD

Two University of Houston professors are working to help keep your heart beating stronger and longer simply by monitoring the temperature of your fingertip.

6 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Annual heart disease and stroke rates in China to rise up to 73% by 2030: Research

Annual heart disease and stroke rates in China will rise by up to 73 percent by 2030, given an aging population and other increased risk factors, without policies and prevention efforts aimed at controlling blood pressure and smoking, according to research from Columbia University Medical Center published in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.

6 May 2010

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

ThromboGenics NV and co-development partner BioInvent International announce today positive results from their Phase II trial of TB-402. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery.

6 May 2010

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

Researchers at Johns Hopkins have discovered that a compound in dark chocolate may protect the brain after a stroke by increasing cellular signals already known to shield nerve cells from damage.

6 May 2010

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Physician scientists at the Texas Heart Institute at St. Luke's Episcopal Hospital (THI at St. Luke's) have been awarded a grant of almost $1.5 million by the National Institutes of Health for research into treatments for patients with end-stage heart failure that would combine heart-assist devices and adult stem-cell treatments.

6 May 2010

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Cardiogenesis Corporation, a leading developer of surgical products used in the treatment of cardiac patients suffering from severe angina, today reported financial results for its first quarter ended March 31, 2010.

6 May 2010

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

According to a new survey conducted by The National Heart Foundation, the forbidding ambulance costs are preventing timely calls to the emergency by at least one in 10 heart attack victims. The Foundation also released a discussion paper released during Heart Week urging free universal ambulance services in all states and territories. Dr Bill Coote in the paper entitled Universal Ambulance Cover has also said that this would prevent many heart attack deaths.

5 May 2010

LightLab Imaging granted FDA clearance for C7-XR Imaging System and C7 Dragonfly Imaging Catheter

LightLab Imaging, Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) technology for vascular and other imaging applications, has received clearance from the U.S. Food and Drug Administration (FDA) for the C7-XR Imaging System and companion C7 Dragonfly Imaging Catheter.

5 May 2010

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

S2S hosts students from Newark Science Park High School for a day of hands-on science

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

Nile Therapeutics completes dose escalation in CD-NP Phase II study for acute decompensated heart failure

THI at St. Luke's reveals new insights on how adult stem cells repair damaged hearts following heart attack

NHLBI grants MU $8.47 million for research on cardiovascular diseases

Amira Pharmaceuticals' LPA1 receptor antagonist program data published in British Journal of Pharmacology

Swedish researchers present a new principle for inhibiting atherosclerosis

Genzyme to initiate $2 billion stock buyback

Australia’s first ever health policy for men

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Measurement of finger temperature to assess individual's risk for CVD

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

RayBiotech announces biomarker grant winners

Annual heart disease and stroke rates in China to rise up to 73% by 2030: Research

ThromboGenics, BioInvent International report positive results from Phase II trial of TB-402 for VTE

Dark chocolate may protect brain after stroke by increasing cellular signals: Researchers

THI at St. Luke's awarded $1.5M NIH grant for study of stem cells with LVADs for end-stage heart failure

Cardiogenesis reports 13% increase in first-quarter 2010 revenue

Forbidding ambulance costs deter heart attack victims from calling ‘000’: National Heart Foundation

LightLab Imaging granted FDA clearance for C7-XR Imaging System and C7 Dragonfly Imaging Catheter

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in